Christopher Pazdan Buys 5,000 Shares of KORU Medical Systems (NASDAQ:KRMD) Stock

KORU Medical Systems, Inc. (NASDAQ:KRMD) COO Christopher Pazdan purchased 5,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was bought at an average price of $3.88 per share, with a total value of $19,400.00. Following the completion of the purchase, the chief operating officer owned 305,131 shares of the company’s stock, valued at approximately $1,183,908.28. This represents a 1.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

KORU Medical Systems Stock Up 3.4%

KRMD stock opened at $3.96 on Wednesday. The business has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $4.84. The company has a market cap of $181.88 million, a price-to-earnings ratio of -79.20 and a beta of 0.43. KORU Medical Systems, Inc. has a twelve month low of $2.63 and a twelve month high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.76 million during the quarter, compared to the consensus estimate of $11.28 million. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%. On average, equities research analysts anticipate that KORU Medical Systems, Inc. will post -0.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KRMD. B. Riley Financial raised their price target on KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Tuesday, April 21st. Wall Street Zen downgraded KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a research note on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.25.

Institutional Trading of KORU Medical Systems

Several hedge funds have recently added to or reduced their stakes in KRMD. First Light Asset Management LLC raised its position in shares of KORU Medical Systems by 5.1% in the second quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after buying an additional 226,700 shares in the last quarter. Topline Capital Management LLC grew its position in KORU Medical Systems by 1.1% during the third quarter. Topline Capital Management LLC now owns 3,648,240 shares of the company’s stock worth $13,973,000 after buying an additional 39,893 shares in the last quarter. Vanguard Group Inc. grew its position in KORU Medical Systems by 2.9% during the third quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company’s stock worth $8,218,000 after buying an additional 60,109 shares in the last quarter. Geode Capital Management LLC grew its position in KORU Medical Systems by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock worth $5,944,000 after buying an additional 16,062 shares in the last quarter. Finally, Acuitas Investments LLC raised its holdings in KORU Medical Systems by 89.6% in the 3rd quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock valued at $2,923,000 after acquiring an additional 360,594 shares in the last quarter. 58.60% of the stock is owned by institutional investors and hedge funds.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.